Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Agrees To One-Month Inventory Limit Under SEC Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement marks first definition of "normal" inventory levels for pharmaceutical industry. Bristol agrees to $150 mil. civil penalty to resolve investigation into "channel stuffing" during 2000-2001.

You may also be interested in...



Bristol Settles DoJ "Channel Stuffing" Investigation For $300 Mil.

The company will take a $249 mil. charge in the second quarter, in addition to a first quarter charge of $51 mil. The monies will be added to a shareholder fund created under a separate, earlier settlement with SEC. CEO Dolan loses his chairman's title under the pact, and Bristol agrees to cooperate with investigations of former executives.

Bristol Settles DoJ "Channel Stuffing" Investigation For $300 Mil.

The company will take a $249 mil. charge in the second quarter, in addition to a first quarter charge of $51 mil. The monies will be added to a shareholder fund created under a separate, earlier settlement with SEC. CEO Dolan loses his chairman's title under the pact, and Bristol agrees to cooperate with investigations of former executives.

Bristol Increases Reserves In Anticipation Of Further SEC Action

The company has set aside $140 mil. as its minimum estimated liability from ongoing investigations into accounting issues. Bristol already paid $150 mil. to settle civil claims filed by SEC.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel